# India HbA1c Market

> India HbA1c Market Research Report Information by Product Type (Reagents & Kits and Instruments [Bench Top Devices and Hand-Held Devices), by Technology (Ion-Exchange HPLC, Immunoassay, Boronate Affinity HPLC, Enzymatic Assay, Turbidimetric Inhibition Immunoassay (TINIA), and Others), by Application (Thalassemia, Sickle Cell Anaemia, and Type 2 Diabetes), by End User (Hospitals and Clinics, Diagnostic Laboratories, and Others) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.04%
- **2024:** $ 0.28 Billion
- **2025:** $ 0.3 Billion
- **2035:** $ 0.44 Billion
- **Key Players:** Roche Diagnostics (IN), Abbott Laboratories (IN), Siemens Healthineers (IN), Boehringer Ingelheim (IN), Danaher Corporation (IN), A. Menarini Diagnostics (IN), Trinity Biotech (IN), MediWise (IN)

**Report ID:** MRFR/HC/20443-CR · **Pages:** 208 · **Author:** Rahul Gotadki · **Last Updated:** April 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-hba1c-market-22043

---

## Market Summary

## **India HbA1c Market Overview**

As per MRFR analysis, the India HbA1c Market Size was estimated at 0.13 (USD Billion) in 2024. The India HbA1c Market Industry is expected to grow from 0.14 (USD Billion) in 2025 to 0.29 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.49% during the forecast period (2025 - 2034).

The India market growth is propelled by several key factors, notably the rising prevalence of type 2 diabetes and increased prevalence of thalassemia and sickle cell among India.

** Source: Secondary Research, Primary Research, MRFR Database and Analyst Review**

## **India HbA1c Market Trends**

### **Increased prevalence of thalassemia and sickle cell among India**

HbA1c testing is a crucial tool for type 2 diabetes patients to monitor their blood sugar control and manage their condition effectively. Regular HbA1c monitoring assists physicians and patients to assess diabetes management, adjust treatment as needed, and reduce the risk of complications. India is often referred to as the “Diabetes Capital of the World,” and the factors that are driving India to become a diabetes capital are India has the largest population in the world and India is undergoing rapid urbanization, leading to lifestyle changes.

Moreover, India has a high burden of [thalassemia](../../../reports/thalassemia-treatment-market-8595) and sickle cell diseases, with a significant number of individuals affected by these conditions. According to estimates, India has the highest number of thalassemia patients in the world, with approximately 50 million carriers and over 10,000 thalassemia major patients. The increasing prevalence of these conditions in the country has led to a rising demand for HBa1c testing. Healthcare providers and laboratories are increasingly performing these tests to diagnose and monitor individuals with thalassemia and sickle cell diseases.

Thus, the demand for HbA1c testing among Indians is increasing due to rising prevalence of type 2 diabetes, thalassemia, and sickle cell disease.

## **India HbA1c Market Segment Insights**

### **India HbA1c Market Product Type Insights**

Based on product type, the India HbA1c market is segmented into reagents & kits and instruments. Furthermore, the instrument segment bifurcated into bench top devices and hand-held devices. Reagents & kits held the largest market share in 2022 and instruments is anticipated to register the highest CAGR from 2022 to 2032. This growth is driven by rising diabetes prevalence and advancement in technology to development of more accurate and user-friendly HbA1c testing kits and devices.

For instance, in November 2021, as per the World Health Organization, there were an estimated 77 million people suffering from type 2 diabetes, especially those over the age of 18.

### **India HbA1c Market Technology Insights**

Based on technology, the India HbA1c market has been segmented into ion-exchange HPLC, [immunoassay](../../../reports/immunoassay-market-5841), boronate affinity HPLC, enzymatic assay, turbidimetric inhibition immunoassay (TINIA), and others. Immunoassay held the largest market share in 2022 and turbidimetric inhibition immunoassay is anticipated to register the highest CAGR from 2022 to 2032. This growth reflects due to some major factors such as increasing research and development activity across the country, quality control and regulatory compliance, and rising demand of accurate and reliable measurements of glycated hemoglobin levels.

**FIGURE 2: INDIA HBA1C MARKET, BY TECHNOLOGY, 2022 & 2032 (USD BILLION)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **India HbA1c Market Application Insights**

Based on application, the India HbA1c market has been segmented into thalassemia, sickle cell anaemia, and type 2 diabetes. Type 2 diabetes held the largest market share in 2022 and is anticipated to register the highest CAGR from 2025 to 2034. This is due to the increased prevalence of thalassemia in India and the growing prevalence of sickle cell anemia in India.

Furthermore, patient education and awareness for early diagnosis of type 2 diabetes and a sedentary lifestyle are the major factors contributing to the increase in type 2 diabetes among Indians, fueling the growth of the market during the forecast period.

### **India HbA1c Market End User Insights**

Based on end user, the India HbA1c market is segmented into hospitals and clinics, diagnostic laboratories, and others. Hospitals and clinics held the largest market share in 2022 due to diagnostic accuracy and reliability and their rising adaptation to integrated healthcare services. Moreover, the diagnostic laboratories segment is anticipated to register the highest CAGR during the forecast period because of rising awareness regarding high accuracy, reliability, and consistency in HbA1c  testing results.

## **India HbA1c Market Key Market Players & Competitive Insights**

The India HbA1c testing market is distinguished by the presence of numerous local players catering to HbA1c testing products that are evolving at a rapid pace. Furthermore, the rising prevalence of type 2 diabetes and increased prevalence of thalassemia and sickle cell among India is further driving the growth of India HbA1c testing market during the forecast period. The major players have adopted a strategy of obtaining regulatory approval from government agencies for their products and signing contracts and agreements to broaden their reach and reduce operational costs.

Furthermore, PTS Diagnostics (US) manufactures point-of-care biometric testing devices. The company offers diagnostic products and accessories to the healthcare industry through its signature products, which include the CardioChek family of lipid and glucose analyzers & products, A1CNow + systems, portable analyzers that provide a HbA1c measurement, a tobacco-detection device, and many other devices. Additionally, PTS Diagnostics offers the PTS ConnectTM solution, a turnkey population health management (PHM) platform, to urgent care centers, retail clinics, and health and wellness enterprises. Moreover, the company launched the A1CNow+ Controls for the A1CNow+ Test System.

A1CNow+ Controls can be kept at room temperature for seven days, in the refrigerator for eight months, or in the freezer for up to three years. Within minutes, both solution’s levels each in a dropper-style vial can be used. Its goal is to ensure accurate A1C measurements. Customers can buy this product from the US, EU, UK, and including India.

### **Key Companies in the India HbA1c market includes**

- [Siemens Healthineers AG](https://www.siemens-healthineers.com/press/releases/pr-20190514018shs.html) (Germany)
- PTS Diagnostics (US)
- ARKRAY, Inc (Japan)
- Abbott (US)
- Bio-Rad Laboratories, Inc (US)
- Transasia Bio-Medicals (India)
- Hoffmann-La Roche Ltd. (Switzerland)
- Beckman Coulter, Inc. (US)
- LumiraDx (UK)
- HemoCue AB (Sweden)

## **India HbA1c Market Industry Developments**

**February 2022:** Abbott (US) moved into collaboration with health-tech partners BeatO (India), PharmEasy (India), Sugar.fit (India), GOQii (India), Zyla Health (India), 1MG (India), Healthifyme (India), and Fitterfly (India) to lead a new era of holistic diabetes management. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which around 6.5 million users can access through 1MG and PharmEasy.

**March 2020:** PTS Diagnostics (US) launched the A1CNow+ Controls for the A1CNow+ Test System. A1CNow+ Controls can be kept at room temperature for seven days, in the refrigerator for eight months, or in the freezer for up to three years. Within minutes, both solution’s levels each in a dropper-style vial can be used. Its goal is to ensure accurate A1C measurements. Customers can buy this product from the US, EU, UK, and including India.

## **India HbA1c Market Segmentation**

### **India HbA1c Market Product Type Outlook**

### **India HbA1c Market Technology Outlook**

- Ion-Exchange HPLC
- Immunoassay
- Boronate affinity HPLC
- Enzymatic Assay
- Turbidimetric Inhibition Immunoassay (TINIA)
- Others

### **India HbA1c Market Application Outlook**

- Thalassemia
- Sickle Cell Anaemia
- Type 2 Diabetes

### **India HbA1c Market End User Outlook**

- Hospitals and Clinics
- Diagnostic Laboratories
- Others

## Market Drivers

### Rising Healthcare Expenditure

The increasing healthcare expenditure in India is a pivotal driver for the India Hba1C Market. As the government and private sectors allocate more resources towards healthcare, the demand for diabetes management tools, including Hba1C testing, is likely to rise. In 2025, India's healthcare expenditure reached approximately 3.6% of its GDP, reflecting a growing recognition of the importance of chronic disease management. This trend suggests that more funds will be directed towards diabetes care, enhancing accessibility to Hba1C testing. Furthermore, with the rise in disposable incomes, patients are more willing to invest in preventive healthcare measures, which could further bolster the India Hba1C Market. The combination of increased healthcare spending and a focus on chronic disease management indicates a robust growth trajectory for Hba1C testing in the country.

### Rising Incidence of Lifestyle Diseases

The rising incidence of lifestyle diseases in India is a significant driver for the India Hba1C Market. With urbanization and changing dietary habits, the prevalence of diabetes and related conditions is on the rise. As of 2025, it is estimated that nearly 10% of the adult population in India is affected by diabetes, necessitating regular monitoring of blood glucose levels through Hba1C testing. This trend underscores the urgent need for effective diabetes management solutions. Furthermore, the increasing burden of lifestyle diseases has prompted healthcare providers to advocate for routine Hba1C testing as part of preventive healthcare measures. Consequently, the India Hba1C Market is likely to expand as more individuals seek to manage their health proactively, leading to a greater demand for Hba1C testing services.

### Growing Awareness of Diabetes Management

The growing awareness surrounding diabetes management is significantly influencing the India Hba1C Market. Educational initiatives by healthcare professionals and organizations have led to a better understanding of the importance of regular Hba1C testing among patients. In recent years, campaigns have highlighted the correlation between Hba1C levels and diabetes complications, prompting individuals to seek regular testing. This heightened awareness is reflected in the increasing number of diabetes screening programs across urban and rural areas. As of 2025, it is estimated that over 70 million people in India are living with diabetes, and the demand for effective monitoring tools like Hba1C tests is expected to surge. Consequently, the India Hba1C Market is poised for growth as more individuals prioritize their health and seek out testing services.

### Technological Innovations in Diagnostics

Technological innovations in diagnostics are transforming the landscape of the India Hba1C Market. The advent of point-of-care testing devices and home monitoring systems has made Hba1C testing more accessible and convenient for patients. These advancements allow for quicker results and improved patient compliance, as individuals can monitor their glucose levels more effectively. In 2025, the market for point-of-care testing devices in India is projected to grow at a compound annual growth rate (CAGR) of 12%, indicating a strong shift towards innovative solutions in diabetes management. Additionally, the integration of telemedicine and digital health platforms is facilitating remote consultations and follow-ups, further enhancing the appeal of Hba1C testing. As technology continues to evolve, the India Hba1C Market is likely to benefit from these innovations, leading to improved patient outcomes.

### Increasing Government Support and Policies

Increasing government support and favorable policies are crucial drivers for the India Hba1C Market. The Indian government has implemented various initiatives aimed at combating diabetes, including the National Program for Prevention and Control of Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS). These programs emphasize the importance of regular health screenings, including Hba1C testing, to manage diabetes effectively. In 2025, the government is expected to allocate additional funds to enhance diabetes care infrastructure, which may include subsidizing Hba1C testing for low-income populations. This proactive approach not only raises awareness but also improves access to essential diagnostic tools. As government policies continue to evolve, the India Hba1C Market is likely to experience sustained growth, driven by increased accessibility and affordability of testing services.

## Future Outlook

The India Hba1C Market is projected to grow at a 4.04% CAGR from 2025 to 2035, driven by increasing diabetes prevalence, technological advancements, and enhanced healthcare access.

**New opportunities:**

- Expansion of telehealth services for remote HbA1c monitoring Development of point-of-care testing devices for rapid results Partnerships with pharmacies for home testing kit distribution

By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare dynamics.

## Segment Insights

### By Test Type: Laboratory Testing (Largest) vs. Point of Care Testing (Fastest-Growing)

In the India Hba1C Market, the market share distribution reveals Laboratory Testing as the dominant player among the test types, holding a significant portion of the overall testing market. This segment benefits from established infrastructure and trust among healthcare providers and patients due to its proven accuracy and reliability. Meanwhile, Point of Care Testing is rapidly gaining traction, catering to the need for quicker and more accessible testing solutions in clinical settings.

Testing Method: Laboratory Testing (Dominant) vs. Point of Care Testing (Emerging)

Laboratory Testing is characterized by its rigorous processes and high standards, often preferred for delivering precise Hba1C results in clinical atmospheres. It involves sophisticated equipment and skilled personnel, making it the choice for comprehensive medical assessments. On the other hand, Point of Care Testing represents a shift towards more convenient testing options, providing instant results at the point of care. This method appeals particularly to patients who prioritize swift testing and is fuelling its rapid growth in the market.

### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the India Hba1C market, the distribution of end users shows that hospitals represent the largest segment. They play a crucial role in managing chronic conditions such as diabetes, leading to a higher volume of Hba1C testing. By contrast, clinics have steadily gained traction, reflecting a shift towards more accessible healthcare solutions. This growing preference for clinic-based testing is reshaping patient access to Hba1C management, expanding its reach to more individuals.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals remain a dominant force in the Hba1C testing landscape due to their comprehensive diagnostic capabilities and established patient relationships. They tend to invest in advanced technology and skilled professionals for accurate testing. Alternatively, clinics represent an emerging segment by offering personalized and quicker services, catering to increasing patient demand for convenience. Their agility in adapting to new technologies positions them well in the market, often providing a more patient-friendly experience. This dynamic encourages a more proactive approach to diabetes management, making clinics an appealing option for many patients.

### By Distribution Channel: Online Pharmacies (Largest) vs. Retail Pharmacies (Fastest-Growing)

The distribution of Hba1C testing solutions in India is primarily dominated by online pharmacies, leveraging their extensive reach and convenience for patients. Retail pharmacies represent a significant portion of the market but are overshadowed by the rapid growth and preference for online options. As healthcare becomes more digitized, the share of online pharmacies continues to expand, providing easy access to essential health tests and services.

Pharmacies: Online (Dominant) vs. Retail (Emerging)

Online pharmacies have established themselves as the dominant force within the distribution of Hba1C testing solutions, offering consumers the convenience of purchasing from home and often at competitive prices. Retail pharmacies, while still vital, are increasingly seen as an emerging market segment, adapting to the shift towards digital solutions by enhancing their service offerings and integrating technology. This evolution is marked by attempts to capture customers through personalized services and improved accessibility, although they still play a crucial role in areas where online services may not reach as effectively.

### By Technology: Enzymatic Assays (Largest) vs. Immunoassays (Fastest-Growing)

In the India Hba1C market, the distribution of market share among the technology segment values reveals that Enzymatic Assays currently hold the largest portion. This segment is preferred due to its proven accuracy, reliability, and widespread acceptance in clinical laboratories. Immunoassays, while smaller, are rapidly catching up as they offer advantages in terms of speed and simplicity of procedure, making them increasingly popular in point-of-care settings.

Technology: Enzymatic Assays (Dominant) vs. Immunoassays (Emerging)

Enzymatic Assays have established themselves as the dominant technology in the India Hba1C market, renowned for their precise measurement and cost-effectiveness. These assays are primarily utilized in laboratories owing to their standardized protocols and strong analytical performance. On the other hand, Immunoassays are emerging as a formidable competitor due to their high sensitivity and rapid turnaround time, making them suitable for point-of-care testing. Their increased adoption is driven by the growing need for user-friendly healthcare solutions and the trend towards decentralization of laboratory services, catering to a broader population.

### By Patient Demographics: Adults (Largest) vs. Elderly (Fastest-Growing)

In the India Hba1C market, the patient demographic segment is primarily composed of adults, who hold the largest market share. This group reflects the increasing prevalence of diabetes in the working-age population, coupled with lifestyle changes and rising obesity rates influencing health. Additionally, the elderly population represents a significant portion of this segment, benefitting from the overall growth trend in diabetes management and care among older individuals.

Adults (Dominant) vs. Elderly (Emerging)

Adults remain the dominant demographic in the India Hba1C market due to their high susceptibility to diabetes and related conditions, driven partially by sedentary lifestyles and dietary habits. On the other hand, the elderly segment is emerging rapidly, characterized by an increasing demand for Hba1C testing as the awareness of diabetes management improves. This trend is further supported by growing healthcare access and increased screening programs targeted at older populations. Both segments are critical, with adults maintaining a stable demand while the elderly represent an important growth opportunity in the healthcare market.

## Competitive Benchmarking

The Hba1C Market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on digital transformation. Key players such as Roche Diagnostics (Switzerland), Abbott Laboratories (United States), and Siemens Healthineers (Germany) are at the forefront, leveraging their technological prowess to enhance diagnostic accuracy and patient outcomes. Roche Diagnostics (Switzerland) emphasizes innovation in its product offerings, particularly in point-of-care testing solutions, which are gaining traction in the Indian healthcare ecosystem. Meanwhile, Abbott Laboratories (United States) is focusing on expanding its [digital health](https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636) initiatives, integrating advanced analytics to improve patient management and engagement. Siemens Healthineers (Germany) is also investing in regional expansion, aiming to enhance its market presence through strategic collaborations with local healthcare providers.
The business tactics employed by these companies reflect a concerted effort to localize manufacturing and optimize supply chains, thereby enhancing operational efficiency. The market structure appears moderately fragmented, with several players vying for market share, yet the collective influence of these key players is significant. Their strategies not only foster competition but also drive advancements in technology and service delivery, ultimately benefiting healthcare providers and patients alike.
In November 2025, Roche Diagnostics (Switzerland) announced the launch of a new Hba1C testing device designed for rapid results in outpatient settings. This strategic move is likely to enhance the accessibility of diabetes management tools, aligning with the growing demand for efficient healthcare solutions in India. The introduction of this device may position Roche as a leader in the point-of-care segment, potentially increasing its market share.
In December 2025, Abbott Laboratories (United States) entered into a partnership with a leading telehealth provider to integrate its Hba1C testing services into remote patient monitoring platforms. This collaboration is indicative of Abbott's commitment to digital health, suggesting that the company is keen on leveraging technology to improve patient outcomes and streamline diabetes management. Such initiatives may enhance Abbott's competitive edge in a rapidly evolving market.
In January 2026, Siemens Healthineers (Germany) unveiled a new AI-driven analytics platform aimed at optimizing laboratory workflows and enhancing diagnostic accuracy. This innovation reflects Siemens' focus on integrating advanced technologies into its operations, which could significantly improve efficiency and patient care in the Hba1C testing domain. The strategic importance of this development lies in its potential to set Siemens apart from competitors by offering superior diagnostic solutions.
As of January 2026, the competitive trends in the Hba1C Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing service delivery. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to changing market dynamics.

## Recent News & Developments

**February 2022:** Abbott (US) moved into collaboration with health-tech partners BeatO (India), PharmEasy (India), Sugar.fit (India), GOQii (India), Zyla Health (India), 1MG (India), Healthifyme (India), and Fitterfly (India) to lead a new era of holistic diabetes management. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which around 6.5 million users can access through 1MG and PharmEasy.

**March 2020:** PTS Diagnostics (US) launched the A1CNow+ Controls for the A1CNow+ Test System. A1CNow+ Controls can be kept at room temperature for seven days, in the refrigerator for eight months, or in the freezer for up to three years. Within minutes, both solution’s levels each in a dropper-style vial can be used. Its goal is to ensure accurate A1C measurements. Customers can buy this product from the US, EU, UK, and including India.

## Report Scope

| MARKET SIZE 2024 | 0.285(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.297(USD Billion) |
| MARKET SIZE 2035 | 0.441(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.04% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche Diagnostics (IN), Abbott Laboratories (IN), Siemens Healthineers (IN), Boehringer Ingelheim (IN), Danaher Corporation (IN), A. Menarini Diagnostics (IN), Trinity Biotech (IN), MediWise (IN) |
| Segments Covered | Test Type, End User, Distribution Channel, Technology, Patient Demographics |
| Key Market Opportunities | Rising demand for advanced diabetes management solutions drives growth in the India Hba1C Market. |
| Key Market Dynamics | Rising demand for advanced diagnostic tools drives innovation in the India HbA1c market amid regulatory changes. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India Hba1C market?**
A: The India Hba1C market was valued at 0.285 USD Billion in 2024.

**Q: What is the projected market size for the India Hba1C market by 2035?**
A: The projected valuation for the India Hba1C market is 0.441 USD Billion by 2035.

**Q: What is the expected CAGR for the India Hba1C market during the forecast period?**
A: The expected CAGR for the India Hba1C market from 2025 to 2035 is 4.04%.

**Q: Which companies are the key players in the India Hba1C market?**
A: Key players in the India Hba1C market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Boehringer Ingelheim.

**Q: What are the main segments of the India Hba1C market by test type?**
A: The main segments by test type include Laboratory Testing, Point of Care Testing, and Self-Monitoring.

**Q: How did the Laboratory Testing segment perform in 2024?**
A: In 2024, the Laboratory Testing segment was valued at 0.115 USD Billion.

**Q: What is the expected performance of the Home Care segment by 2035?**
A: The Home Care segment is projected to reach 0.134 USD Billion by 2035.

**Q: What distribution channels are significant in the India Hba1C market?**
A: Significant distribution channels include Online Pharmacies, Retail Pharmacies, and Direct Sales.

**Q: What technology segments are present in the India Hba1C market?**
A: Technology segments include Enzymatic Assays, Immunoassays, and Capillary Electrophoresis.

**Q: How does the market size for adults compare to that of children in 2024?**
A: In 2024, the market size for adults was 0.15 USD Billion, whereas for children it was 0.05 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-hba1c-market-22043*